FDA Approval of LISRAYA for Adults with Dermatomyositis – Roivant
Roivant announced that the FDA has approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. DM is… read more.
Roivant announced that the FDA has approved LISRAYA (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily. DM is… read more.
AbbVie announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction for the treatment of adult… read more.
New research in the International Journal of Clinical Practice suggests that workplace psychological stress may impair erectile function in young men by affecting certain stress management pathways in the brain… read more.
The risk of being hospitalised for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined… read more.
Eli Lilly and Company announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound (tirzepatide) for weight management… read more.
NICE(UK) updated recommendation their 6 August 2026 recommendation to expand the population in line with the marketing authorisation. We also updated the technology name and title to more… read more.
Patients’ responses to questions routinely raised by oncologists may provide important clues about their chances of survival from chronic lymphocytic leukemia (CLL), according to a new study published in the… read more.
The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress… read more.
Gilead Sciences, Inc. announced that the FDA approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults… read more.
Takeda announced FDA approval of the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. Mimrylo… read more.
An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new research from the University of East Anglia. A study… read more.
Three large studies together show that, although the number of people who smoke is declining, people are taking up smoking at a younger age and vaping has increased,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.